Skip to main content
SpringerLink
Log in

First-line treatment of paediatric tuberculosis requires consideration of disease type and severity followed by careful monitoring

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

The first-line treatment of paediatric tuberculosis (TB) involves long-term treatment with regimens containing multiple anti-TB agents (i.e. isoniazid, rifampicin, pyrazinamide and/or ethambutol). The choice of treatment regimen is based on the clinical manifestation of TB, disease severity and the risk of antibacterial resistance. Paediatric patients should be carefully monitored for treatment compliance, response to treatment and drug-related adverse events, of which hepatotoxicity is the most common.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Principi N, Galli L, Lancella L, et al. Recommendations concerning the first-line treatment of children with tuberculosis. Paediatr Drugs. 2016;18(1):13–23.

    Article  PubMed  Google Scholar 

  2. World Health Organization. Tuberculosis: fact sheet no. 104. 2016. http://www.who.int/mediacentre. Accessed 27 Apr 2016.

  3. Piccini P, Chiappini E, Tortoli E, et al. Clinical peculiarities of tuberculosis. BMC Infect Dis. 2014;14(Suppl 1):S4.

    Article  PubMed  PubMed Central  Google Scholar 

  4. World Health Organization. Guidance for national tuberculosis programmes on the management of tuberculosis in children, 2nd ed. 2014. http://www.who.int/tb. Accessed 28 Apr 2016.

  5. TB Alliance. Child-friendly medicines. http://www.tballiance.org/child-friendly-medicines. Accessed 9 May 2016.

  6. Donald PR. Antituberculosis drug-induced hepatotoxicity in children. Pediatr Rep. 2011;3:e16.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Huang YS, Chern HD, Su WJ, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology. 2002;35:883–9.

    Article  CAS  PubMed  Google Scholar 

  8. Wang PY, Xie SY, Hao Q, et al. NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis. Int J Tuberc Lung Dis. 2012;16:589–95.

    Article  PubMed  Google Scholar 

  9. Thee S, Detjen A, Quarcoo D, et al. Ethambutol in paediatric tuberculosis: aspects of ethambutol serum concentration, efficacy and toxicity in children. Int J Tuberc Lung Dis. 2007;11:965–71.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

    Consortia

    Adis Medical Writers

    Ethics declarations

    The article was adapted from Pediatric Drugs 2016;18(1):13–23 [1] by salaried employees of Adis/Springer and was not supported by any external funding.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Adis Medical Writers. First-line treatment of paediatric tuberculosis requires consideration of disease type and severity followed by careful monitoring. Drugs Ther Perspect 32, 330–334 (2016). https://doi.org/10.1007/s40267-016-0317-2

    Download citation

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s40267-016-0317-2

    Keywords

    Search

    Navigation